Finally, a new drug slows Alzheimer’s, but is it worth the price for modest benefit?
Leqembi can slow early progression by months but has safety concerns. Most patients will likely have to wait months to get the IV drug, which will cost about $26,500 a year. Insurers need to decide whether and how much to cover it. Medicare isn’t expected to pay for it until…
Chicago Sun-Times ·
Chicago Sun-Times
The Independent UK
